Drug Database
Back to search

Finland· FI-REL-REL376

Lutopolar

A medroxyprogesterone product containing medroxyprogesterone acetate, registered in Finland by Orion Corporation Orion Pharma. The same ATC class is registered in 9 of our 19 countries.

ATC G03DA02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedLutopolarATCG03DA02REGISTER NO.FI-REL-REL376PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about medroxyprogesterone acetateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Medroxyprogesterone is registered in 9 of 19 countries.

Countries holding a registration under ATC G03DA02 (medroxyprogesterone), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 5 of them publish a price we can compare per daily dose
Search medroxyprogesterone products by name

Medroxyprogesterone · ATC G03DA02

9 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Medroxyprogesterone acetate
Manufacturer
Orion Corporation Orion Pharma
Country
Finland (FI)
ATC code
G03DA02
ATC class
Medroxyprogesterone
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

241 interactions on record for medroxyprogesterone.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check medroxyprogesterone against other medicinesHow interaction checks work

Medroxyprogesterone · interactions on record

241 records

  • 21 severe
  • 213 moderate
  • 7 minor

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • BosentanC02KX01severe
  • GriseofulvinD01AA08severe
  • GriseofulvinD01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Medroxyprogesterone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All medroxyprogesterone products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Depocon, Farlutal
  • Belgium · Depo-Provera, Provera
  • Bulgaria · Фарлутал
  • Czechia · Depo-Provera, Provera
  • Germany · Depo-Clinovir, Mpa
  • Denmark · Depo-Provera, Provera
  • Estonia · Farlutal
  • Spain · Depo-Progevera, Progevera
  • France · Depo Prodasone, Depo Provera
  • United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
  • Croatia · Provera
  • Hungary · Depo-Provera, Provera
  • Ireland · Depo-Provera, Provera
  • Iceland · Depo-Provera
  • Italy · Depo-Provera, Farlutal
  • Luxembourg · Depo-Provera, Provera
  • Latvia · Depo-Provera
  • Netherlands · Depo-Provera, Provera
  • Norway · Depo-Provera, Provera
  • Poland · Depo-Provera, Provera
  • Portugal · Depo-Provera 150
  • Sweden · Depo-Provera, Provera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/79dc0f6a-1811-4c29-a4a5-38a1c1f7a618
GET /v1/drugs/79dc0f6a-1811-4c29-a4a5-38a1c1f7a618?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "5",
  "form": "tabletti",
  "route": null,
  "ddd_unit": "mg",
  "strength": "5 mg",
  "atc_label": "medroksiprogesteroni",
  "ma_number": "3427",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL376",
  "authorised_at": "1966-05-11"
}
API referenceMCP serverPlans

See everything about medroxyprogesterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console